statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

This is a signal that PDSB's price could be shifting from a downtrend to an uptrend. Traders may consider buying the stock or exploring call options...

PDS Biotechnology (PDSB, $4.02) RSI Indicator left the oversold zone on April 01, 2024

PDS Biotechnology (NASDAQ:PDSB - Get Free Report)s stock had its "buy" rating reiterated by analysts at B. Riley in a note issued to investors on Thursday, Benzinga reports. They presently...

PDS Biotechnology (NASDAQ:PDSB) Earns Buy Rating from B. Riley

PDS Biotechnology Co. (NASDAQ:PDSB  Free Report)  Analysts at B. Riley issued their Q1 2024 EPS estimates for PDS Biotechnology in a note issued to investors on Thursday, March 28th. B...

PDS Biotechnology Co. (NASDAQ:PDSB) to Post Q1 2024 Earnings of ($0.40) Per Share, B. Riley Forecasts

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

PDS Biotechnology price target lowered by $3 at B. Riley, here's why

In a report released today, Robert LeBoyer from Noble Financial maintained a Buy rating on PDS Biotechnology (PDSB Research Report), with a price...

Noble Financial Sticks to Its Buy Rating for PDS Biotechnology (PDSB)

Analyst Mayank Mamtani of B.Riley Financial reiterated a Buy rating on PDS Biotechnology (PDSB Research Report), with a price target of $11.00. M...

PDS Biotechnology: Strategic Shift to Triplet Therapy Promises Enhanced Clinical Success

PDS Biotechnology price target lowered to $5 from $16 at Alliance Global Partners

PDS Biotechnology (PDSB, $3.84) RSI Indicator left the oversold zone on March 27, 2024

Q4 2023 PDS Biotechnology Corp Earnings Call Transcript

PDS Biotechnology Corporation (NASDAQ:PDSB) Q4 2023 Earnings Call Transcript March 27, 2024
PDS Biotechnology Corporation isnt one of the 30 most popular stocks among hedge funds at the end of...

PDS Biotechnology Corporation (NASDAQ:PDSB) Q4 2023 Earnings Call Transcript

PDS Biotechnology Corp. engages in the development of clinical-stage immunotherapies to treat various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its product, PDS0101, is an off the shelf immunotherapeutic that is administered by subcutaneous injection. The company was founded by Frank K. Bedu-Addo in 2005 and is headquartered in Princeton, NJ.

Watchers	8,014
52-Wk Low	$2.59
52-Wk High	$10.27

Volume	1.84M
52-Wk High	$10.27
52-Wk Low	$2.59

PDSB PDS Biotechnology Corporation

About

Feed

News

Sentiment

Earnings

Fundamentals